CN107921009B - 腹膜治疗液 - Google Patents

腹膜治疗液 Download PDF

Info

Publication number
CN107921009B
CN107921009B CN201680042681.5A CN201680042681A CN107921009B CN 107921009 B CN107921009 B CN 107921009B CN 201680042681 A CN201680042681 A CN 201680042681A CN 107921009 B CN107921009 B CN 107921009B
Authority
CN
China
Prior art keywords
peritoneal
bca
treatment fluid
biocompatibility
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680042681.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107921009A (zh
Inventor
G·格伦茨曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opterion Health AG
Original Assignee
Opterion Health AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health AG filed Critical Opterion Health AG
Priority to CN201910196687.3A priority Critical patent/CN110075307A/zh
Publication of CN107921009A publication Critical patent/CN107921009A/zh
Application granted granted Critical
Publication of CN107921009B publication Critical patent/CN107921009B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
CN201680042681.5A 2015-07-20 2016-07-19 腹膜治疗液 Active CN107921009B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910196687.3A CN110075307A (zh) 2015-07-20 2016-07-19 腹膜治疗液

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2 2015-07-20
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910196687.3A Division CN110075307A (zh) 2015-07-20 2016-07-19 腹膜治疗液

Publications (2)

Publication Number Publication Date
CN107921009A CN107921009A (zh) 2018-04-17
CN107921009B true CN107921009B (zh) 2020-12-11

Family

ID=53785450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680042681.5A Active CN107921009B (zh) 2015-07-20 2016-07-19 腹膜治疗液
CN201910196687.3A Pending CN110075307A (zh) 2015-07-20 2016-07-19 腹膜治疗液

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910196687.3A Pending CN110075307A (zh) 2015-07-20 2016-07-19 腹膜治疗液

Country Status (23)

Country Link
US (2) US20180221303A1 (cg-RX-API-DMAC7.html)
EP (2) EP3120842A1 (cg-RX-API-DMAC7.html)
JP (1) JP6448847B2 (cg-RX-API-DMAC7.html)
KR (2) KR102266889B1 (cg-RX-API-DMAC7.html)
CN (2) CN107921009B (cg-RX-API-DMAC7.html)
AU (1) AU2016296216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001005B1 (cg-RX-API-DMAC7.html)
CA (1) CA2990532C (cg-RX-API-DMAC7.html)
CO (1) CO2018000236A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124467T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324951T3 (cg-RX-API-DMAC7.html)
ES (1) ES2880796T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211319T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055208T2 (cg-RX-API-DMAC7.html)
LT (1) LT3324951T (cg-RX-API-DMAC7.html)
MX (1) MX387020B (cg-RX-API-DMAC7.html)
PL (1) PL3324951T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324951T (cg-RX-API-DMAC7.html)
RS (1) RS62142B1 (cg-RX-API-DMAC7.html)
RU (1) RU2718908C2 (cg-RX-API-DMAC7.html)
SI (1) SI3324951T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100428T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017013120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds
WO2025265015A1 (en) * 2024-06-20 2025-12-26 Barinta Therapeutics, Inc. Flavylium cations and electrolyte complexes thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
MXPA02001472A (es) * 1999-08-10 2002-07-02 Ml Lab Plc Metodo para suministrar agentes terapeuticos utilizando una solucion de dextrina.
WO2001028544A2 (en) 1999-10-15 2001-04-26 The Dow Chemical Company Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007049796A2 (en) 2005-10-26 2007-05-03 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
JP2010535221A (ja) * 2007-07-31 2010-11-18 イーエルシー マネージメント エルエルシー レスベラトロール誘導体を含有する化粧用組成物
US20110281957A1 (en) * 2008-11-26 2011-11-17 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
JP5778584B2 (ja) * 2009-01-19 2015-09-16 ライコード・リミテツド カロテノイドとポリフェノールとの相乗的組み合わせ
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
US9919004B2 (en) * 2012-04-24 2018-03-20 The University Of British Columbia Polymer-based dialysate
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
活性氧与高糖对人腹膜间皮细胞增殖的影响;唐知还等;《中华肾脏病杂志》;20030831;第19卷(第4期);第223-227页 *
白藜芦醇对腹膜透析液作用下人腹膜间皮细胞线粒体活性氧产生的影响;伍军等;《医学研究杂志》;20131130;第42卷(第11期);第43-46页 *

Also Published As

Publication number Publication date
PT3324951T (pt) 2021-07-20
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
EP3324951B1 (en) 2021-05-26
RU2018106122A (ru) 2019-08-20
SI3324951T1 (sl) 2021-09-30
DK3324951T3 (da) 2021-08-23
US11160766B2 (en) 2021-11-02
ES2880796T3 (es) 2021-11-25
AU2016296216A1 (en) 2017-12-14
RS62142B1 (sr) 2021-08-31
KR20190025759A (ko) 2019-03-11
LT3324951T (lt) 2021-07-26
HK1251176A1 (zh) 2019-01-25
HUE055208T2 (hu) 2021-11-29
US20180221303A1 (en) 2018-08-09
HRP20211319T1 (hr) 2021-11-26
EP3120842A1 (en) 2017-01-25
WO2017013120A1 (en) 2017-01-26
PL3324951T3 (pl) 2021-12-13
KR102266889B1 (ko) 2021-06-18
US20200022926A1 (en) 2020-01-23
MX2018000336A (es) 2018-05-22
JP2018522894A (ja) 2018-08-16
RU2018106122A3 (cg-RX-API-DMAC7.html) 2019-10-10
RU2718908C2 (ru) 2020-04-15
AU2016296216B2 (en) 2019-05-02
CN107921009A (zh) 2018-04-17
KR20180048577A (ko) 2018-05-10
EP3324951A1 (en) 2018-05-30
CY1124467T1 (el) 2022-07-22
BR112018001005B1 (pt) 2023-11-28
BR112018001005A2 (pt) 2022-09-06
CA2990532C (en) 2020-07-14
JP6448847B2 (ja) 2019-01-09
CO2018000236A2 (es) 2018-06-12
CA2990532A1 (en) 2017-01-26
CN110075307A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
US11160766B2 (en) Peritoneal therapeutic fluid
ES2370478T3 (es) Carbohidratos antiadhesivos.
US11185514B2 (en) Aqueous solution comprising a polyphenol
ES2691872T3 (es) Aminofucoidan como un vector para la fibrinolisis en enfermedades trombóticas
HK40011489A (en) Peritoneal therapeutic fluid
JP5474353B2 (ja) ヒドロゲルを形成する熱可塑性の中性化されたキトサン組成物、凍結乾燥体、およびこれらを生成する方法
HK1251176B (en) Peritoneal therapeutic fluid
CN116650425B (zh) 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用
RU2749443C2 (ru) Углеводные композиции для диализа
GB2345247A (en) Pyruvic acid formulations
HK1254524B (en) Aqueous solution comprising a stilbenoid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251176

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant